Cargando…
Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
This scientific commentary refers to ‘Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease’, by Mattsson-Carlgren et al. (doi:10.1093/brain/awaa286).
Autores principales: | Teunissen, Charlotte E, Thijssen, Elisabeth H, Verberk, Inge M W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719020/ https://www.ncbi.nlm.nih.gov/pubmed/33278818 http://dx.doi.org/10.1093/brain/awaa329 |
Ejemplares similares
-
Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021) -
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021) -
Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023) -
Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022) -
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)